Mode
Text Size
Log in / Sign up
Phase 2 N=17 Treatment

Limbal Stem Cell Deficiency (LSCD) Treatment With Cultivated Stem Cell (CALEC) Graft

Limbal Stem Cell Deficiency

Enrolled (actual)
17
Serious AEs
5.9%
Results posted
Jan 2025
Primary outcome: Primary: Primary Safety Events of Interest — 1; 0; 0; 0 Participants

Study Design & Population

Study type
Interventional
Phase
Phase 2
Interventions
Biopsy to collect limbal epithelial stem cells that will be cultivated into a graft (Procedure); Cultivation of Limbal epithelial cells into a graft (Biological); CALEC Transplant (Procedure)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Massachusetts Eye and Ear Infirmary
Primary completion
Mar 2023

Outcome Measures

OutcomeResultp-value
PRIMARY
Primary Safety Events of Interest
1; 0; 0; 0; 0; 0
PRIMARY
Manufacturing Feasibility Measures
14
SECONDARY
Measure of Transplant Efficacy
7; 1; 11; 0; 10; 1

Summary

The main aim of the study is to determine the safety and feasibility of a cultivated autologous limbal epithelial cell (CALEC) transplantation in the treatment of limbal stem cell deficiency.

Eligibility Criteria

Inclusion Criteria

  • Male or female participants age 18 to <90 years old at time of enrollment
  • Ability of a subject or guardian/legal representative to provide written informed consent and to comply with study assessments for the full duration of the study.
  • Patients with unilateral limbal stem cell deficiency (LSCD) as determined by conjunctivalization of the cornea defined by fibrovascular pannus more than 2 mm from the limbus for greater than or equal to 6 clock hours.
  • Additional optional criteria:
  • Lack of limbal palisades of Vogt for greater than or equal to 9 clock hours
  • Goblet cell presence as defined by impression cytologic criteria

Exclusion Criteria

  • Corneal or ocular surface infection within 30 days prior to study entry or CALEC transplantation
  • Ocular surface malignancy
  • Uncontrolled diabetes with most recent HgA1c greater than 8.5%
  • Renal Failure with eGFR below 60 mL/min per 1.73 m2
  • Aspartate aminotransferase and alanine aminotransferase levels greater than 3 times institutional upper limit of normal
  • Total bilirubin greater than 2 times institutional upper limit of normal (except patients with known Gilbert's syndrome)
  • Platelet levels less than 100, 000 or greater than 450,000 per microliter
  • Hemoglobin levels of less than 11.0 g/dL in men or less than 10.0 g/dL in women
  • Prothrombin time greater than 16 seconds and activated partial thromboplastin time greater than 35 seconds in patients not taking warfarin and an international normalized ratio greater than 3 in patients taking warfarin
  • Inability to tolerate monitored anesthesia
  • HIV infection or AIDS
  • Active Hepatitis B or C
  • Pregnancy (positive test) or lactation
  • Participation in another simultaneous medical investigation or trial
  • Severe cicatricial eye disease
  • Severe dry eye disease as determined by Schirmer's test less than 1mm in at least one eye.
  • Any medical, psychiatric, debilitating disease/disorder or social condition that in the judgment of the investigator would interfere with or serve as a contraindication to adherence to the study protocol or ability to give informed consent.
  • Signs of current infection, including fever and current treatment with antibiotics.
  • History of allo-limbal transplantation
  • Presence of allergy to the CALEC graft or any of the chemical components within its formulation.

Exclusion Based on Donor Eye:

  • Conjunctivalization of the cornea defined by fibrovascular pannus more than 2 mm from the limbus for greater than or equal to 3 clock hours
  • Lack of limbal palisades of Vogt for greater than or equal to 3 clock hours
  • History of allo-limbal transplantation
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02592330). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search